7.2 C
New York
Tuesday, December 5, 2023

There Is A Quest For Clarity Surrounding Clover Health Investments Corp (NASDAQ: CLOV) Volatility

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Clover Health Investments Corp (CLOV) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.1449, or -12.82%, to $0.9851. The Clover Health Investments Corp has recorded 995,892 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Clover Health Reports Third Quarter 2023 Results; Highlights Continued Improvement in Financial Performance and Improved 2023 Guidance.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Stocks Info

This NASDAQ-listed company operates within the Healthcare Plans industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $1.13 and fluctuated between $1.1800 as its day high and $1.0800 as its day low. The current market capitalization of Clover Health Investments Corp is $547.89M. A total of 7.08 million shares were traded on the day, compared to an average of 3.89M shares.

Insider trades can also provide insight into a stock’s future direction. During the recent three months, CLOV has seen 5 BUY and 7 SELL insider trades, representing the acquisition of 2,032,202 and the disposition of 601,574 shares. Over the last 12 months, there were 14 BUYs and 17 SELLs from insiders. Insiders purchased 13,219,228 shares during that period but sold 1,675,895.

In the most recent transaction, Loengard Anna U bought 11,000 shares of CLOV for 1.30 per share on Sep 06. After the transaction, the Director now owns 10,000 company shares.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CLOV in the last 3 months, the mean price target is $2.00 with high estimates of $3.00 and low estimates of $1.50. In terms of 52-week highs and lows, CLOV has a high of $1.63 and a low of $0.71.

As of this writing, CLOV has an earnings estimate of -$0.11 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.09 per share and a lower estimate of -$0.13. The company reported an EPS of -$0.15 in the last quarter, which was 16.70% higher than expectations of -$0.18.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CLOV’s latest balance sheet shows that the firm has $791.19M in Cash & Short Term Investments as of fiscal 2021. There were $27.83M in debt and $372.62M in liabilities at the time. Its Book Value Per Share was $0.69, while its Total Shareholder’s Equity was $539.32M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CLOV is Buy with a score of 3.20.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles